Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 5, 2009, Pages 499-505

  Samaras, Katherine ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Adipokines; Diabetes mellitus; Fat; Glucose; HIV; Inflammation; Insulin resistance; Insulin secretion; Lipoatrophy; Lipodystrophy; Metabolism; Obesity

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; INSULIN; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; PENTAMIDINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETOGENESIS; DISORDERS OF CARBOHYDRATE METABOLISM; FASTING GLUCOSE; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HEPATITIS C; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPOATROPHY; LIPODYSTROPHY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMOCYSTOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANTI-HIV AGENTS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PREVALENCE;

EID: 65449127827     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819c291b     Document Type: Review

References (70)

1. UNAIDS. World health Organisation. December 2006. AIDS epidemic update. Joint United Nations Programme on HV/AIDS. Available at: http://www.unaids.org/ en/HIV-data/epi2006/default.asp. Accessed January 8, 2008.
2. International Diabetes Federation. Prevalence data in 2007. Available at: http://www.idf.org/home/index.cfm?node=24. Accessed January 8, 2008.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care. 1998;21: 1414-1431.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(Suppl 1) S43-S48.
6. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114-121.
7. Kilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:46-50.
8. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-1184.
9. Coyle P, Carr AD, Depczynski BB, et al. Diabetes mellitus associated with pentamidine use in HIV-infected patients. Med J Aust. 1996;165:587-588.
10. Ubukata E, Mokuda O, Nagata M, et al. A pentamidine-treated acquired immunodeficiency syndrome patient associated with sudden onset diabetes mellitus and high tumor necrosis factor alpha level. J Diabetes Complications. 1997;11:256-258.
11. Lu CP, Wu HP, Chuang LM, et al. Pentamidine-induced hyperglycemia and ketosis in acquired immunodeficiency syndrome. Pancreas. 1995;11: 315-316.
12. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997;127:947.
13. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med. 1997;127:948.
14. Dube MP, Johnson DL, Currier JS, et al. Protease-inhibitor-associated hyperglycaemia. Lancet. 1997;350:713-714.
15. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS. 1998;12:F51-F58.
16. Carr A, Samaras K, Thorisdottir A, et al. Natural history, diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet. 1999;353:2094-2099.
17. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32: 130-139.
18. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for newonset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31: 1224-1229.
19. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet. 2003;361:726-735.
20. Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIVpositive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2001;26:443-448.
21. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
22. van der Valk M, Gisolf EH, Reiss P, et al, and the Prometheus Study Group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-855.
23. Gallant JE, Staszewski S, Pozniak AL, et al, and the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292: 191-201.
24. Yoon C, Gulick RM, Hoover DR, et al. Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;37: 1464-1469.
25. Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive peptide, and hypoadiponectinemia. Diabetes Care. 2007;30:113-119.
26. Salehian B, Bilas J, Bazargan M, et al. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc. 2005;97:1088-1092.
27. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557-561.
28. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolismamong HIV-infected women. Clin Infect Dis. 2005;40:1492-1499.
29. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.
30. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739-1745.
31. Yazicioglu G, Isitan F, Altunbas H, et al. Insulin resistance in chronic hepatitis C. Int J Clin Pract. 2004;58:1020-1022.
32. Mehta SH, Moore RD, Thomas DL, et al. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr. 2003;33:577-584.
33. Ledergerber B, Ferrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111-119.
34. Panz VR, Joffe BI. Impact of HIV infection and AIDS on prevalence of type 2 diabetes in South Africa in 2010. BMJ. 1999;318:1351A. Letter.
35. Levitt NS, Bradshaw D. The impact of HIV/AIDS on type 2 diabetes prevalence and diabetes healthcare needs in South Africa: projections for 2010. Diabet Med. 2006;23:103-104. Letter.
36. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Circulation. 2004;109:433-438.
37. Alberti KGMM, Zimmet P, Shaw J. The IDF consensus worldwide definition of the metabolic syndrome. Lancet. 2005;366:1059-1062.
38. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIVinfected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132-137.
39. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458-466.
40. Palacios R, Santos J, Gonzalez M, et al. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS. 2007;18:184-187.
41. Wand H, Calmy A, Carey DL, et al. Metabolic Syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infection. AIDS. 2007;21:2445-2453.
42. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 (HIV) infection. J Antimicrob Chemother. 2008;61:238-245.
43. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51:7-18.
44. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of proteaseinhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet. 1998;351:1881-1883.
45. Gan SK, Samaras K, Carr A, et al. Antiretroviral therapy, insulin resistance and lipodystrophy. Diabetes Obes Metab. 2001;3:67-71.
46. Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc. 2007;66: 82-95.
47. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30:1219-1225.
48. Bonora E, Kiechl S, Willeit J, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007;30:318-324.
49. Hommes MJ, Romijn JA, Endert E, et al. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism. 1991;40:651-656.
50. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebocontrolled study. AIDS. 2002;16:F1-F8.
51. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007;21:2183-2190.
52. Blumer RME, van Vonderen MGA, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227-236.
53. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275: 20251-20254.
54. Hertel J, Struthers H, Horj CB, et al. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem. 2004;279:55147-55152.
55. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation and induces insulin resistance. Diabetes. 2001;50:1378-1388.
56. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475-481.
57. Tong Q, Sankale JL, Hadigan CM, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab. 2003;88:1559-1564.
58. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes. 2002;51:3163-3169.
59. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666-E1673.
60. Mallon PWG, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of mitochondrial DNA depletion. J Infect Dis. 2005;191:1686-1696.
61. Woerle HJ, Mariuz RR, Meyer C, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52:918-925.
62. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-F70.
63. Schutt M, Zhou J, Meier M, et al. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol. 2004;183:445-454.
64. Koster JC, Remedi MS, Qui H, et al. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003;52:1695-1700.
65. Mynarcik DC, McNurian MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immunne Defic Syndr. 2000;25:312-321.
66. Dolan SE, Hadigan C, Killiliea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Aquir Immune Defic Syndr. 2005;39:44-54.
67. Kosmiski L, Kuritzkes D, Lichtenstein K, et al. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther. 2003;8:9-15.
68. Mynarcik DC, Combs T, McNurian MA, et al. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immunne Defic Syndr. 2002;31:514-520.
69. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther. 2004;9:555-564.
70. Samaras K, Gan SK, Peake P, et al. Proinflammatory markers, insulin sensitivity and cardiometabolic risk factors in treated HIV-infection. Obesity. 2009;17:53-59.